浏览全部资源
扫码关注微信
1.贵州医科大学临床医学院,贵阳 550004
2.贵州医科大学附属医院皮肤科,贵阳 550001
3.贵州医科大学大健康产业技术发展研究中心,贵阳 550025
硕士研究生。研究方向:中药现代化抗皮肤肿瘤。 E-mail:1627316427@qq.com
教授,博士生导师。研究方向:中药现代化抗皮肤鳞癌的机制及药物筛选。电话:0851-86770846。E-mail:2692327139@ qq.com
纸质出版日期:2023-05-15,
收稿日期:2022-09-29,
修回日期:2023-03-29,
扫 描 看 全 文
唐姗姗,荣冬芸,王叶等.二氢色原酮拼接多环吡咯螺环氧化吲哚类化合物3m抗皮肤鳞状细胞癌的作用及机制 Δ[J].中国药房,2023,34(09):1086-1092.
TANG Shanshan,RONG Dongyun,WANG Ye,et al.Anti-cutaneous squamous cell carcinoma effect and mechanism of dihydrochromone-spliced polycyclic pyrrole-spiroepoxidole compound 3m[J].ZHONGGUO YAOFANG,2023,34(09):1086-1092.
唐姗姗,荣冬芸,王叶等.二氢色原酮拼接多环吡咯螺环氧化吲哚类化合物3m抗皮肤鳞状细胞癌的作用及机制 Δ[J].中国药房,2023,34(09):1086-1092. DOI: 10.6039/j.issn.1001-0408.2023.09.12.
TANG Shanshan,RONG Dongyun,WANG Ye,et al.Anti-cutaneous squamous cell carcinoma effect and mechanism of dihydrochromone-spliced polycyclic pyrrole-spiroepoxidole compound 3m[J].ZHONGGUO YAOFANG,2023,34(09):1086-1092. DOI: 10.6039/j.issn.1001-0408.2023.09.12.
目的
2
探究二氢色原酮拼接多环吡咯螺环氧化吲哚类化合物3m抗皮肤鳞状细胞癌的作用及机制。
方法
2
以人皮肤鳞状细胞癌A431、Colo-16细胞为研究对象,采用CCK-8法检测不同浓度(5、10、20、40、80 μmol/L)3m作用24、48、72 h后对A431、Colo-16细胞增殖的影响,并计算培养48 h时的半数抑制浓度(IC
50
)。将A431、Colo-16细胞分别分为对照组和3m低、高浓度组(15、30 μmol/L),加入相应药物或培养基培养48 h后,采用倒置显微镜观察细胞形态变化,检测细胞克隆形成率、迁移率、侵袭数、细胞周期分布和凋亡率,检测细胞中Janus激酶2/信号转导及转录激活因子3(JAK2/STAT3)信号通路相关蛋白[JAK2、STAT3、B细胞淋巴瘤2(Bcl-2)、Bcl-2相关X蛋白(Bax)]磷酸化或表达水平及其mRNA的表达水平。
结果
2
不同浓度3m作用24、48、72 h后均能显著抑制A431、Colo-16细胞增殖(
P
<0.01),48 h时的IC
50
分别为20.36、23.72 μmol/L。作用48 h后,与对照组比较,3m低、高浓度组A431、Colo-16细胞排列稀疏、连接松散;克隆形成率、迁移率、侵袭数,细胞中JAK2、STAT3、Bcl-2 mRNA表达水平,JAK2、STAT3蛋白磷酸化水平和Bcl-2蛋白表达水平均显著降低/减少(
P
<0.01);细胞周期G2期占比、凋亡率、Bax蛋白和mRNA表达水平均显著升高(
P
<0.01);上述作用均呈剂量依赖性。
结论
2
3m可呈剂量依赖性地抑制皮肤鳞状细胞癌A431、Colo-16细胞的增殖、克隆形成、迁移、侵袭能力,其作用机制与抑制JAK2/STAT3信号通路活性,诱导细胞凋亡有关。
OBJECTIVE
2
To study the effect and mechanism of dihydrochromone-spliced polycyclic pyrrole-spiroepoxidole compound 3m on cutaneous squamous cell carcinoma.
METHODS
2
Using human cutaneous squamous cell carcinoma A431 and Colo-16 cells as research subjects, CCK-8 assay was used to detect the effects of different concentrations of 3m (5, 10, 20, 40, 80 μmol/L) on the proliferation of A431 and Colo-16 cells after 24, 48 and 72 hours; the median inhibitory concentration (IC
50
) was calculated at 48 h of treatment. A431 and Colo-16 cells were divided into control group, 3m low-concentration and high-concentration groups (15, 30 μmol/L). After treated with relevant drugs or culture medium for 48 h, the morphological changes of cells in each group were observed by inverted microscope. Clone formation rate, migration rate and number of cell invasions, cell cycle distribution and apoptosis rate were detected. The phosphorylation, or expression of Janus kinase 2/signal transducer and activator of transcription 3 (JAK2/STAT3) signaling pathway related proteins [JAK2, STAT3, B-cell lymphocyte-2 (Bcl-2), Bcl-2-associated X protein (Bax)], and their mRNA expression in cells were detected.
RESULTS
2
3m could significantly inhibit the proliferation of A431 and Colo-16 cells after treated for 24, 48, 72 h (
P
<0.01), and IC
50
of them were 20.36, 23.72 μmol/L, respectively. After 48 hours of treatment, compared with control group, A431 and Colo-16 cells arranged sparsely and loosely connected in 3m low-concentration and high-concentration groups. The clone formation rate, migration rate, number of cell invasions, mRNA expressions of JAK2,STAT3 and Bcl-2, the phosphorylation of JAK2 and STAT3, protein expression of Bcl-2 were significantly decreased/weakened (
P
<0.01). Proportion of cell cycle in G2 phase, apoptosis rate, protein and mRNA expression of Bax were increased significantly (
P
<0.01); and all the above effects were in dose-dependent manner.
CONCLUSIONS
2
3m can inhibit the proliferation, clone formation, migration and invasion abilities of cutaneous squamous cell carcinoma A431 and Colo-16 cells in a dose-dependent manner, the mechanism of which may be associated with inhibiting the activity of JAK2/STAT3 signaling pathway, and inducing cell apoptosis.
皮肤鳞状细胞癌二氢色原酮多环吡咯螺环氧化吲哚增殖凋亡迁移侵袭
dihydrochromonepolycyclic pyrrole-spiroepoxidoleproliferationapoptosismigrationinvasion
CORCHADO-COBOS R,GARCÍA-SANCHA N,GONZÁLEZ-SARMIENTO R,et al. Cutaneous squamous cell carcinoma:from biology to therapy[J]. Int J Mol Sci,2020,21(8):2956.
FIRNHABER J M. Basal cell and cutaneous squamous cell carcinomas:diagnosis and treatment[J]. Am Fam Physician,2020,102(6):339-346.
FARBERG A S,FITZGERALD A L,IBRAHIM S F,et al. Current methods and caveats to risk factor assessment in cutaneous squamous cell carcinoma (cSCC):a narrative review[J]. Dermatol Ther (Heidelb),2022,12(2):267-284.
STRATIGOS A J,GARBE C,DESSINIOTI C,et al. European interdisciplinary guideline on invasive squamous cell carcinoma of the skin:part 1. epidemiology,diagnostics and prevention[J]. Eur J Cancer,2020,128:60-82.
DROLL S,BAO X M. Oh,the mutations you’ll acquire! A systematic overview of cutaneous squamous cell carcinoma[J]. Cell Physiol Biochem,2021,55(S2):89-119.
CLAVEAU J,ARCHAMBAULT J,ERNST D S,et al. Multidisciplinary management of locally advanced and metastatic cutaneous squamous cell carcinoma[J]. Curr Oncol,2020,27(4):e399-e407.
董维维,王先恒,宋继庭,等. 基于天然产物的抗肿瘤缀合物的研究进展[J]. 化学研究与应用,2022,34(3):460-467.
刘婷婷,岳静,陈爽,等. 新型二氢色原酮拼接多环吡咯螺环氧化吲哚类化合物的无催化剂合成及其抗白血病活性[J]. 合成化学,2019,27(6):451-455.
吴相欢,吴丹,王关炼,等. 新型双螺环吡咯酮氧化吲哚并二氢色原酮类化合物的合成[J]. 合成化学,2020,28(6):537-542.
CHEN S,JING Y,LIU X L,et al. One-pot multicomponent construction of chromanone-fused pyrrolidinyl spirooxindole collections through a decarboxylative 1,3-dipolar[3 + 2]cycloaddition reaction[J]. Synth Commun,2019,49(18):2425-2435.
GREEN A C,OLSEN C M. Cutaneous squamous cell carcinoma:an epidemiological review[J]. Br J Dermatol,2017,177(2):373-381.
徐圣文. 二氢色原酮并环戊烷螺环化合物的不对称合成及其抗肿瘤活性研究[D]. 贵阳:贵州大学,2020.
OGATA D,TSUCHIDA T. Systemic immunotherapy for advanced cutaneous squamous cell carcinoma[J]. Curr Treat Options Oncol,2019,20(4):30.
LEAL-ESTEBAN L C,FAJAS L. Cell cycle regulators in cancer cell metabolism[J]. Biochim Biophys Acta Mol Basis Dis,2020,1866(5):165715.
OBENG E. Apoptosis (programmed cell death) and its signals :a review[J]. Revista Brasleira De Biol,2021,81(4):1133-1143.
KETELUT-CARNEIRO N,FITZGERALD K A. Apoptosis,pyroptosis,and necroptosis-oh my! the many ways a cell can Die[J]. J Mol Biol,2022,434(4):167378.
BANERJEE S,BIEHL A,GADINA M,et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases:current and future prospects[J]. Drugs,2017,77(5):521-546.
XIN P,XU X Y,DENG C J,et al. The role of JAK/STAT signaling pathway and its inhibitors in diseases[J]. Int Immunopharmacol,2020,80:106210.
MENGIE AYELE T,TILAHUN MUCHE Z,BEHAILE TEKLEMARIAM A,et al. Role of JAK2/STAT3 signaling pathway in the tumorigenesis,chemotherapy resistance,and treatment of solid tumors:a systemic review[J]. J Inflamm Res,2022,15:1349-1364.
TANG C,ZHAO C C,YI H,et al. Traditional Tibetan medicine in cancer therapy by targeting apoptosis pathways[J]. Front Pharmacol,2020,11:976.
BALACHANDRAN C,ARUN Y ,SANGEETHA B,et al. In vitro and in vivo anticancer activity of 2-acetyl-benzylamine isolated from Adhatoda vasica L. leaves[J]. Biomed Pharmacother,2017,93:796-806.
HAFEZI S,RAHMANI M. Targeting Bcl-2 in cancer: advances,challenges,and perspectives[J]. Cancers (Basel),2021,13(6):1292.
0
浏览量
1
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构